| 產品名稱 |
ACHN |
| 商品貨號 |
B163905 |
| Organism |
Homo sapiens, human |
| Tissue |
kidney; derived from metastatic site: pleural effusion |
| Product Format |
frozen |
| Morphology |
epithelial |
| Culture Properties |
adherent |
| Biosafety Level |
1
Biosafety classification is based on U.S. Public Health Service Guidelines, it is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country. |
| Disease |
renal cell adenocarcinoma |
| Age |
22 years |
| Gender |
male |
| Ethnicity |
Caucasian |
| Applications |
ACHN may be of use for antiproliferative studies using human interferons or interferon inducers. |
| Storage Conditions |
liquid nitrogen vapor temperature |
| Derivation |
The ACHN cell line was initiated in November, 1979 from the malignant pleural effusion of a 22-year-old Caucasian male with widely metastatic renal adenocarcinoma (autopsy confirmed). Cells were seeded directly to culture flasks in Eagle's MEM with 10% FBS, then maintained and passaged 150 days in flasks. Cells were then inoculated subcutaneously into nude mice. After 4 weeks, palpable, locally invasive tumors were noted. Both the original cells (ACHN) and those recovered from nude mouse tumors were growth-inhibited by human interferons. |
| Clinical Data |
22 years Caucasian male |
| Tumorigenic |
Yes |
| Effects |
Yes, in nude mice (Tumors developed within 21 days at 100% frequency (5/5) in nude mice inoculated subcutaneously with 10(7) cells) |
| Comments |
Growth is inhibited by human interferon [Hogan, T. F., personal communication]. |
| Complete Growth Medium |
The base medium for this cell line is ATCC-formulated Eagle's Minimum Essential Medium, Catalog No. 30-2003. To make the complete growth medium, add the following components to the base medium: fetal bovine serum to a final concentration of 10%.
|
| Subculturing |
Volumes are given for a 75 cm2 flask. Increase or decrease the amount of dissociation medium needed proportionally for culture vessels of other sizes.
- Remove and discard culture medium.
- Briefly rinse the cell layer with 0.25% (w/v) Trypsin - 0.53 mM EDTA solution to remove all traces of serum which contains trypsin inhibitor.
- Add 2.0 to 3.0 mL of Trypsin-EDTA solution to flask and observe cells under an inverted microscope until cell layer is dispersed (usually within 5 to 15 minutes).
Note: To avoid clumping do not agitate the cells by hitting or shaking the flask while waiting for the cells to detach. Cells that are difficult to detach may be placed at 37°C to facilitate dispersal.
- Add 6.0 to 8.0 mL of complete growth medium and aspirate cells by gently pipetting.
- Add appropriate aliquots of the cell suspension to new culture vessels.
- Incubate cultures at 37°C.
Subcultivation Ratio: A subcultivation ratio of 1:2 to 1:3 is recommended
Medium Renewal: 2 to 3 times per week |
| Cryopreservation |
Freeze medium: Complete growth medium, 95%; DMSO, 5% Storage temperature: liquid nitrogen vapor temperature |
| Culture Conditions |
Atmosphere: air, 95%; carbon dioxide (CO2), 5% Temperature: 37°C |
| STR Profile |
Amelogenin: X CSF1PO: 11 D13S317: 12 D16S539: 12,13 D5S818: 12 D7S820: 9,11 THO1: 8 TPOX: 8,11 vWA: 16,17 |
| Isoenzymes |
G6PD, B |
| Name of Depositor |
TF Hogan |
| Deposited As |
Homo sapiens |
| Year of Origin |
November, 1979 |
| References |
Tumors developed within 21 days at 100% frequency (5/5) in nude mice inoculated subcutaneously with 10(7) cells
The ACHN cell line was initiated in November, 1979 from the malignant pleural effusion of a 22-year-old Caucasian male with widely metastatic renal adenocarcinoma (autopsy confirmed). Cells were seeded directly to culture flasks in Eagle's MEM with 10% FBS, then maintained and passaged 150 days in flasks. Cells were then inoculated subcutaneously into nude mice. After 4 weeks, palpable, locally invasive tumors were noted. Both the original cells (ACHN) and those recovered from nude mouse tumors were growth-inhibited by human interferons.
Kochevar J. Blockage of autonomous growth of ACHN cells by anti-renal cell carcinoma monoclonal antibody 5F4. Cancer Res. 20: 2968-2972, 1990. PubMed: 2334900
|
